1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67738D8D05F38658385257B2800681B06
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/7738D8D05F38658385257B2800681B06!OpenDocument
18
19OpenDocument
2044.200.122.214
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Brand Management and Product Leadership » Product Marketing and Innovation

Document Excerpt: Using a Franchise Approach to Support Multiple Products: Enhancing Sales Force Effectiveness and Corporate Reputation

DB Image

ID: MD-355


Features:

12 Info Graphics

20 Data Graphics

275+ Metrics

5 Narratives

1 Best Practices


Pages/Slides: 4


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".

To return to the study abstract to purchase the full study
- click here.

This excerpt includes research findings and metrics from document #5242 "Using a Franchise Approach to Support Multiple Products: Enhancing Sales Force Effectiveness and Corporate Reputation."

Industries Profiled:
Consumer Products; Diagnostic; Pharmaceutical; Medical Device; Biopharmaceutical; Health Care; Biotech; Market Research; Utilities; Chemical; Clinical Research; Laboratories


Companies Profiled:
Bayer Healthcare; Shionogi Inc.; Roche Diagnostics; Mylan; GlaxoSmithKline ; Drager; CareFusion; B.Braun; Astellas; Entelos; Alcon; Siren Interactive; AstraZeneca; Nonin; Menarini Group; Hikma; Novartis; Nico ; Lupin; Centurion; Covidien; Galpha Laboratories; Catalent Pharma Solutions; Genentech; Almirall; Abbott; Sandoz; Johnson & Johnson; Dr Reddy's Laboratories; Merck; Meda Pharmaceuticals; Sanofi; Amylin; Teva Pharmaceutical Industries Ltd; Glenmark; Boehringer Ingelheim; Wockhardt; Novo Nordisk; Ranbaxy; Daiichi Pharmaceutical Co.; Ltd.; Roche; Baxter Healthcare; Medtronic; Shire; UCB Pharma; Stryker; Gilead Sciences; Biogen Idec; Boston Scientific; Zydus Cadila; Janssen; cipla

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.